. Author manuscript; available in PMC: 2020 Nov 1.

Published in final edited form as: J Thorac Oncol. 2019 Jun 12;14(11):1970–1981. doi: 10.1016/j.jtho.2019.05.042

Table 2.

Comparison of overall survival and progression free survival from diagnosis in patients with small cell lung cancer (SCLC) and neurologic paraneoplastic syndromes (PNS), SCLC and endocrinologic PNS, or SCLC and no PNS.

	SCLC and neurologic PNS	SCLC and endocrinologic PNS	SCLC and no PNS
Overall Survival	24 months, (16.4 - not reached)	12 months, (8.3 – 15.5)	13 months, (12.2 – 16.0)
Progression Free Survival	14 months, (9.3 - not reached)	6 months, (4.6 – 9.5)	7 months, (6.6 – 8.1)

Data displayed indicates median and 95% confidence interval in months.